(2S,4S)-4-tert-butoxycarbonylamino-pyrrolidine-2,4-dicarboxylic acid dimethyl ester | 911697-29-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4S)-4-tert-butoxycarbonylamino-pyrrolidine-2,4-dicarboxylic acid dimethyl ester
• 英文别名: dimethyl (2S,4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrolidine-2,4-dicarboxylate
• CAS: 911697-29-5
• 化学式: C₁₃H₂₂N₂O₆
• 分子量: 302.327
• InChiKey: DROBUUQGYQCVKB-SDBXPKJASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2S,4S)-4-tert-butoxycarbonylamino-pyrrolidine-2,4-dicarboxylic acid dimethyl ester 、 甲基戊酰氯 在 N,N-(diisopropyl)aminomethylpolystyrene 、 aminomethyl-terminated Tentagel resin 作用下， 以 二氯甲烷 为溶剂， 反应 40.0h， 生成
  参考文献：
  名称：

  [EN] TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE
  [FR] DERIVES DE TRANS PYRROLIDINYLE ET LEUR UTILISATION PHARMACEUTIQUE

  摘要：

  本发明涉及使用式（I）或（II）的trans吡咯烷基，其中：R1、R2或R3是氢或羧基或氨基保护基；R4至R8代表氢或烷基基团；R9代表（R10）n（-R11）m基团，其中R10是-CO-、-CS-、-O-、-S-、-SO-、-SO2-、-COO-、-CONRa-、-N(Ra)CO-、-CSNRa-、-N(Ra)CS-、-N(Ra)-、Rb、芳基，R11是一个极性基团，用于治疗和/或预防与改变谷氨酸能信号和/或功能有关的疾病，以及可以通过改变哺乳动物体内谷氨酸水平或信号传导而受影响的疾病。

  公开号：

  WO2005118533A1
• 作为产物：
  描述：

  L-羟基脯氨酸 在 palladium on activated charcoal sodium hydroxide 、 氯化亚砜 、 草酰氯 、 甲酸铵 、 二甲基亚砜 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 (2S,4S)-4-tert-butoxycarbonylamino-pyrrolidine-2,4-dicarboxylic acid dimethyl ester
  参考文献：
  名称：

  Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): Identification of a new group III metabotropic glutamate receptor selective agonist

  摘要：

  A new family of mGlu receptor orthosteric ligands called APTCs was designed and synthesized using a parallel chemistry approach. Amongst 65 molecules tested on mGlu4, mGlu6 and mGlu8 subtypes, (2S,4S)-4-amino-1-[(E)-3-carboxyacryloyl]pyrrolidine-2,4-dicarboxylic acid (8a06-FP0429) has been shown to be a full mGlu4 agonist and a partial mGlu8 agonist. In addition, 8a06 was shown to be selective versus group I and II mGlu subtypes. A possible explanation for this efficacy difference is proposed by docking experiment performed with molecular model of the receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.062

文献信息

• Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use
  申请人：Schann Stephan

  公开号：US20080027127A1

  公开（公告）日：2008-01-31

  The present invention relates to the use of trans pyrrolidinyl of the formula (I) or (II) in which: R 1 , R 2 or R 3 are hydrogen or a carboxy or amino protecting group; R 4 to R 8 represent hydrogen or an alkyl radical; R 9 represents a (R 10 ) n (—R 11 ) m group wherein R 10 is —CO—, —CS—, —O—, —S—, —SO—, —SO 2 —, —COO—, —CONR a —, —N(R a )CO—, —CSNR a —, —N(R a )CS—, —N(R a )—, R b , aryl, and R 11 is a polar group, for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals.

  本发明涉及使用式（I）或（II）的反式吡咯烷基，其中：R1、R2或R3为氢或羧基或氨基保护基；R4至R8表示氢或烷基基团；R9表示（R10）n（—R11）m基团，其中R10为—CO—、—CS—、—O—、—S—、—SO—、—SO2—、—COO—、—CONRa—、—N（Ra）CO—、—CSNRa—、—N（Ra）CS—、—N（Ra）—、Rb、芳基，而R11为极性基团，用于治疗和/或预防与改变谷氨酸能信号和/或功能相关的疾病和/或可以受到哺乳动物谷氨酸水平或信号改变影响的疾病。
• TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE
  申请人：Faust Pharmaceuticals

  公开号：EP1751098A1

  公开（公告）日：2007-02-14
• [EN] TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DERIVES DE TRANS PYRROLIDINYLE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：FAUST PHARMACEUTICALS

  公开号：WO2005118533A1

  公开（公告）日：2005-12-15

  The present invention relates to the use of trans pyrrolidinyl of the formula (I) or (II) in which: R1, R2 or R3 are hydrogen or a carboxy or amino protecting group; R4 to R8 represent hydrogen or an alkyl radical; R9 represents a (R10)n(-R11)m group wherein R10 is -CO-, -CS-, -O-, -S-, -SO-, -SO2-, -COO-, -CONRa-, -N(Ra)CO-, -CSNRa-, -N(Ra)CS-, -N(Ra)-, Rb, aryl, and R11 is a polar group, for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals.

  本发明涉及使用式（I）或（II）的trans吡咯烷基，其中：R1、R2或R3是氢或羧基或氨基保护基；R4至R8代表氢或烷基基团；R9代表（R10）n（-R11）m基团，其中R10是-CO-、-CS-、-O-、-S-、-SO-、-SO2-、-COO-、-CONRa-、-N(Ra)CO-、-CSNRa-、-N(Ra)CS-、-N(Ra)-、Rb、芳基，R11是一个极性基团，用于治疗和/或预防与改变谷氨酸能信号和/或功能有关的疾病，以及可以通过改变哺乳动物体内谷氨酸水平或信号传导而受影响的疾病。
• Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): Identification of a new group III metabotropic glutamate receptor selective agonist
  作者：Stephan Schann、Christel Menet、Paul Arvault、Géraldine Mercier、Mélanie Frauli、Stanislas Mayer、Nadia Hubert、Nicolas Triballeau、Hugues-Olivier Bertrand、Francine Acher、Pascal Neuville

  DOI：10.1016/j.bmcl.2006.06.062

  日期：2006.9

  A new family of mGlu receptor orthosteric ligands called APTCs was designed and synthesized using a parallel chemistry approach. Amongst 65 molecules tested on mGlu4, mGlu6 and mGlu8 subtypes, (2S,4S)-4-amino-1-[(E)-3-carboxyacryloyl]pyrrolidine-2,4-dicarboxylic acid (8a06-FP0429) has been shown to be a full mGlu4 agonist and a partial mGlu8 agonist. In addition, 8a06 was shown to be selective versus group I and II mGlu subtypes. A possible explanation for this efficacy difference is proposed by docking experiment performed with molecular model of the receptor. (c) 2006 Elsevier Ltd. All rights reserved.